跳至主要内容
临床试验/NCT01412021
NCT01412021已完成不适用

Humira® for Subcutaneous Injection Special Investigation ( All-case Survey ) in Patients With Juvenile Idiopathic Arthritis Study

AbbVie0 个研究点目标入组 375 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
375
主要终点
Change From Baseline in DAS28-4/ESR at Week 12

研究概览

简要总结

This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug:

  • Unknown adverse drug reactions (especially important adverse drug reactions)
  • Incidence and conditions of occurrence of adverse reactions in the clinical setting
  • Factors that may affect the safety and effectiveness of Humira

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
— 至 99 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey

排除标准

  • Contraindications according to the Package Insert
  • Patients who have serious infections
  • Patients who have tuberculosis
  • Patients with a history of hypersensitivity to any ingredient of Humira
  • Patients who have demyelinating disease or with a history of demyelinating disease
  • Patients who have congestive cardiac failure

结局指标

主要结局

Change From Baseline in DAS28-4/ESR at Week 12

时间窗: Baseline, Week 12

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/ESR at Week 4

时间窗: Baseline, Week 4

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/ESR at Week 8

时间窗: Baseline, Week 8

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/ESR at Week 16

时间窗: Baseline, Week 16

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/ESR at Week 24

时间窗: Baseline, Week 24

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, ESR, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/CRP at Week 4

时间窗: Baseline, Week 4

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/CRP at Week 8

时间窗: Baseline, Week 8

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/CRP at Week 12

时间窗: Baseline, Week 12

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/CRP at Week 16

时间窗: Baseline, Week 16

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in DAS28-4/CRP at Week 24

时间窗: Baseline, Week 24

The DAS28 is a validated index of arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, CRP, and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 \[low activity\] to 10 \[high activity\]) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in Serum MMP3 Level at Week 4

时间窗: Baseline, Week 4

Change From Baseline in Serum MMP3 Level at Week 8

时间窗: Baseline, Week 8

Change From Baseline in Serum MMP3 Level at Week 12

时间窗: Baseline, Week 12

Change From Baseline in Serum MMP3 Level at Week 16

时间窗: Baseline, Week 16

Change From Baseline in Serum MMP3 Level at Week 24

时间窗: Baseline, Week 24

Change From Baseline in Physician Global Assessment (VAS) at Week 4

时间窗: Baseline, Week 4

A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.

Change From Baseline in Physician Global Assessment (VAS) at Week 8

时间窗: Baseline, Week 8

A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.

Change From Baseline in Physician Global Assessment (VAS) at Week 12

时间窗: Baseline, Week 12

A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.

Change From Baseline in Physician Global Assessment (VAS) at Week 16

时间窗: Baseline, Week 16

A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.

Change From Baseline in Physician Global Assessment (VAS) at Week 24

时间窗: Baseline, Week 24

A VAS was used for the Physician Global Assessment of disease activity (current status). The left end of the VAS scale (0 mm) signifies the absence of symptoms and the right end (100 mm) signifies maximum disease activity. A negative change from baseline indicates improvement.

Change From Baseline in Anti-Cyclic Citrullinated Peptide Antibodies at Week 24

时间窗: Baseline, Week 24

Change From Baseline in Height at Week 4

时间窗: Baseline, Week 4

Change From Baseline in Height at Week 8

时间窗: Baseline, Week 8

Change From Baseline in Height at Week 12

时间窗: Baseline, Week 12

Change From Baseline in Height at Week 16

时间窗: Baseline, Week 16

Change From Baseline in Height at Week 24

时间窗: Baseline, Week 24

Change From Baseline in Weight at Week 4

时间窗: Baseline, Week 4

Change From Baseline in Weight at Week 8

时间窗: Baseline, Week 8

Change From Baseline in Weight at Week 12

时间窗: Baseline, Week 12

Change From Baseline in Weight at Week 16

时间窗: Baseline, Week 16

Change From Baseline in Weight at Week 24

时间窗: Baseline, Week 24

次要结局

未报告次要终点

研究者

发起方
AbbVie
申办方类型
Industry
责任方
Sponsor

相似试验